**Supplementary Table 5: Logistic regression analysis of factors on admission for mortality**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **Adjusted OR (95% CI)** | **p-value** |
| Age (per decade) | 1.63 (1.37, 1.94) | <0.001 |
| Female sex | 0.67 (0.42, 1.05) | 0.08 |
| Black Race (vs White) | 0.92 (0.52, 1.63) | 0.77 |
| Other/unknown race (vs White) | 3.23 (1.57, 6.65) | 0.001 |
| Cancer | 2.09 (1.14, 3.83) | 0.017 |
| Diabetes | 1.93 (1.19, 3.14) | 0.008 |
| Obesity | 1.23 (0.72, 2.09) | 0.45 |
| HTN | 0.69 (0.35, 1.37) | 0.28 |
| GERD | 1.22 (0.69, 2.16) | 0.49 |
| Stroke | 1.14 (0.55, 2.37) | 0.72 |
| CHF | 1.02 (0.56, 1.86) | 0.94 |
| CVD | 2.20 (0.89, 5.47) | 0.09 |
| Asthma/COPD | 1.15 (0.66, 2.01) | 0.62 |
| Anti-hypertensive use | 0.47 (0.28, 0.80) | 0.005 |
| PPI use | 2.49 (1.56, 3.97) | <0.001 |
| H2RA use | 0.72 (0.25, 2.07) | 0.54 |
| Statin use | 0.85 (0.48, 1.50) | 0.57 |

HTN=hypertension, GERD=gastroesophageal reflux disease, CHF=congestive heart failure, CVD=cardiovascular disease, COPD=chronic obstructive pulmonary disease, PPI=proton pump inhibitor, H2RA=histamine H2-receptor antagonists